Claire Marks1, Rebecca Silvola2, Evgennia Teal3, Sara K Quinney1,2, David M Haas1,2. 1. Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, USA. 2. Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. 3. Regenstrief Institute, Indianapolis, Indiana, USA.
Abstract
OBJECTIVE: To compare associations between individual antidepressants and newborn outcomes. DESIGN: Retrospective cohort study. SETTING: Deliveries in a large, US medical system. POPULATION: Women who received at least one antidepressant prescription 3 months prior to conception through delivery. METHODS: Eligible women had maternal characteristics and newborn outcomes extracted from medical record data. Exposure was defined by the timing of the prescription during pregnancy. MAIN OUTCOME MEASURES: Newborn outcomes (any adaptation syndrome, neonatal intensive care unit (NICU) admission) were analyzed for each antidepressant and compared using standard statistics and multivariable regression compared to exposure to bupropion. Odds of outcomes based on timing of exposure were also explored. RESULTS: A total of 3,694 women were analyzed. Rates of any adaptation syndrome (p < 0.001), NICU admission (p < 0.001), and transient tachypnea of newborn (TTN) (p = 0.006) were significantly different between drugs. Infants exposed to duloxetine had the highest rates of NICU admissions (39.6%) and adaptation syndromes (15.1%). Venlafaxine-exposed infants had the highest rates of TTN (18.2%). Controlling for maternal age, race, insurance, and gestational age at delivery, early pregnancy antidepressant exposure was associated with adaptation syndrome and NICU admission for both duloxetine (adjusted odds ratio (aOR) 2.31 [95% Confidence Interval (CI) 1.11-4.80] and aOR 2.47 [95% CI 1.40-4.34], respectively) and escitalopram (aOR 1.72 [95% CI 1.09-2.70] and aOR 1.64 [95% CI 1.21-2.22], respectively). Exposure in the third trimester was associated with any adaptation syndrome for citalopram, duloxetine, escitalopram, fluoxetine, sertraline, and venlafaxine and NICU admission for bupropion, citalopram, duloxetine, escitalopram, and fluoxetine. CONCLUSION: Duloxetine and escitalopram appear to have the strongest associations with any adaptation syndrome and NICU admission whereas bupropion and sertraline tended to have among the lowest risks of these outcomes. These results can help providers and patients discuss choice of individual antidepressant drugs during pregnancy.
OBJECTIVE: To compare associations between individual antidepressants and newborn outcomes. DESIGN: Retrospective cohort study. SETTING: Deliveries in a large, US medical system. POPULATION: Women who received at least one antidepressant prescription 3 months prior to conception through delivery. METHODS: Eligible women had maternal characteristics and newborn outcomes extracted from medical record data. Exposure was defined by the timing of the prescription during pregnancy. MAIN OUTCOME MEASURES: Newborn outcomes (any adaptation syndrome, neonatal intensive care unit (NICU) admission) were analyzed for each antidepressant and compared using standard statistics and multivariable regression compared to exposure to bupropion. Odds of outcomes based on timing of exposure were also explored. RESULTS: A total of 3,694 women were analyzed. Rates of any adaptation syndrome (p < 0.001), NICU admission (p < 0.001), and transient tachypnea of newborn (TTN) (p = 0.006) were significantly different between drugs. Infants exposed to duloxetine had the highest rates of NICU admissions (39.6%) and adaptation syndromes (15.1%). Venlafaxine-exposed infants had the highest rates of TTN (18.2%). Controlling for maternal age, race, insurance, and gestational age at delivery, early pregnancy antidepressant exposure was associated with adaptation syndrome and NICU admission for both duloxetine (adjusted odds ratio (aOR) 2.31 [95% Confidence Interval (CI) 1.11-4.80] and aOR 2.47 [95% CI 1.40-4.34], respectively) and escitalopram (aOR 1.72 [95% CI 1.09-2.70] and aOR 1.64 [95% CI 1.21-2.22], respectively). Exposure in the third trimester was associated with any adaptation syndrome for citalopram, duloxetine, escitalopram, fluoxetine, sertraline, and venlafaxine and NICU admission for bupropion, citalopram, duloxetine, escitalopram, and fluoxetine. CONCLUSION: Duloxetine and escitalopram appear to have the strongest associations with any adaptation syndrome and NICU admission whereas bupropion and sertraline tended to have among the lowest risks of these outcomes. These results can help providers and patients discuss choice of individual antidepressant drugs during pregnancy.
Authors: Rita Suri; Lori Altshuler; Gerhard Hellemann; Vivien K Burt; Ana Aquino; Jim Mintz Journal: Am J Psychiatry Date: 2007-08 Impact factor: 18.112
Authors: F P Bymaster; L J Dreshfield-Ahmad; P G Threlkeld; J L Shaw; L Thompson; D L Nelson; S K Hemrick-Luecke; D T Wong Journal: Neuropsychopharmacology Date: 2001-12 Impact factor: 7.853
Authors: Stephen M. Stahl; James F. Pradko; Barbara R. Haight; Jack G. Modell; Carol B. Rockett; Susan Learned-Coughlin Journal: Prim Care Companion J Clin Psychiatry Date: 2004
Authors: Kayla N Anderson; Jennifer N Lind; Regina M Simeone; William V Bobo; Allen A Mitchell; Tiffany Riehle-Colarusso; Kara N Polen; Jennita Reefhuis Journal: JAMA Psychiatry Date: 2020-12-01 Impact factor: 21.596